Targeted Therapy
Approved for: NSCLC
Biomarker: EGFR
Erlotinib (Tarceva) approved Targeted Therapy for Non-small cell lung cancer (NSCLC) that is metastatic and has certain EGFR gene mutations.
It may be used:
- As first-line therapy.
- In patients on maintenance therapy or whose disease has gotten worse after treatment with chemotherapy.
